logo-loader
viewSkinBioTherapeutics PLC

SkinBioTherapeutics CEO hails 'significant scientific milestone' with cosmetic skincare programme

SkinBioTherapeutics PLC's (LON:SBTX) CEO Stuart Ashman speaks to Proactive's Andrew Scott soon after updating investors on the progress of its cosmetic skincare programme and plans for a psoriasis food supplement trial. Sederma, its partner in the cosmetics programme and a division of Croda International PLC (LON:CRDA), has successfully replicated the lysate manufacturing process and achieved the same performance from the company’s SkinBiotix technology. They're now working to validate a scale up of the manufacturing process at different volume levels. Meanwhile he says they've established a protocol for its self-managed psoriasis food supplement trial and are proceeding with the study.

Quick facts: SkinBioTherapeutics PLC

Price: 19.5 GBX

AIM:SBTX
Market: AIM
Market Cap: £24.98 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

SkinBioTherapeutics assessing options for a 'rapid trial' of its food supplement

SkinBioTherapeutics PLC (LON:SBTX) CEO Stuart Ashman tells Proactive London's Andrew Scott they're looking at all routes possible to get its psoriasis product into the hands of those that need it as they assesses options for a fast-track human study. It's part of their collaboration with...

on 7/7/20

2 min read